Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Strides Receives USFDA Approval for Amantadine Hydrochloride Softgel Capsules
Details : USFDA approved generic version of Amantadine Hydrochloride, a NMDA inhibitor, which is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus.
Product Name : Symmetrel-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 21, 2022
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Receives USFDA Approval for Amantadine Extended-Release Capsules
Details : Amantadine Hydrochloride, a NMDA inhibitor, which is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy.
Product Name : Gocovri-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 09, 2024
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Duke Clinical Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 12, 2024
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Duke Clinical Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Bora Pharmaceuticals
Deal Size : $210.0 million
Deal Type : Acquisition
CDMO Bora Pharmaceuticals Buys Generics Manufacturer Upsher-Smith for $210M
Details : Bora acquires Upsher-Smith’s product portfolio, including Amantadine hydrochloride for treating influenza A virus infections.
Product Name : Amantadine HCl-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 18, 2024
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Bora Pharmaceuticals
Deal Size : $210.0 million
Deal Type : Acquisition
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Bora Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Bora Pharmaceuticals Completes Acquisition of Upsher-Smith
Details : Through the acquisition, Bora will commercialize Amantadine HCl-Generic, which is an NMDA receptor inhibitor. It is indicated for the treatment of influenza A infections and Parkinsonism.
Product Name : Amantadine HCl-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 04, 2024
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Bora Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Supernus Pharmaceuticals
Deal Size : $450.0 million
Deal Type : Acquisition
Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals
Details : Acquistion will strengthens Parkinson’s disease portfolio with GOCOVRI (amantadine) extended release capsules, the first and only FDA-approved medicine indicated for the treatment of both OFF and dyskinesia in patients with Parkinson’s disease receiv...
Product Name : Gocovri
Product Type : Other Small Molecule
Upfront Cash : $450.0 million
November 24, 2021
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Supernus Pharmaceuticals
Deal Size : $450.0 million
Deal Type : Acquisition
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Supernus Pharmaceuticals
Deal Size : $450.0 million
Deal Type : Acquisition
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio
Details : The transaction will provide Supernus with two marketed products: GOCOVRI (amantadine) extended release capsules, indicated for both OFF and dyskinesia in patients with Parkinson’s disease and Osmolex ER (amantadine) tablets, approved for Parkinson’s...
Product Name : Gocovri
Product Type : Other Small Molecule
Upfront Cash : $450.0 million
November 10, 2021
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Supernus Pharmaceuticals
Deal Size : $450.0 million
Deal Type : Acquisition
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Data Analysis Supports GOCOVRI for Motor Complications for People With PD
Details : At week 12, participants treated with GOCOVRI reported statistically significant improvements in motor control for daily activities compared to placebo (least-squares mean changes from baseline of –3.4 points for GOCOVRI and –1.4 for placebo).
Product Name : Gocovri
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 06, 2021
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Medical Research Agency Poland | Leszek Giec Upper-Silesian Medical Centre
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Amantadine Treatment in COVID-19 Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 07, 2021
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Medical Research Agency Poland | Leszek Giec Upper-Silesian Medical Centre
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Adamas Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Adamas Completes Acquisition of OSMOLEX ER®
Details : Through this acquisition, OSMOLEX ER joins the Adamas portfolio which includes GOCOVRI® extended-release capsules for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy with or without concomitant dopamin...
Product Name : Osmolex ER
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 01, 2021
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Adamas Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition